Edison Investment Research Comments on Vertex Pharmaceuticals on VX-661 Data

In a report published Friday, Edison Investment Research analyst Jason Zhang commented on Vertex Pharmaceuticals VRTX. In the report, Zhang noted, “Vertex's remarkable c $7.2bn (62%) increase in market capitalisation last week, on the back of VX-661 Phase IIa top-line data in cystic fibrosis (CF) patients with two copies of F580del mutations, poses a difficult question for investors. While the valuation reflects the market's confidence in the strength of its potential franchise in CF – possibly worth up to $10bn in peak sales – it also assumes a high probability of success. Vertex is now the undisputed leader in CF with one approved (Kalydeco, ivacaftor) drug and three clinical candidates (VX-809, -661 and -983) in the pipeline, but Edison cautions that the risk is now asymmetric to the downside.” Vertex Pharmaceuticals closed on Thursday at $80.32.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsEdison Investment Research
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!